Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401915 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL2307496 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29383465 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL119558 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL3732490 | 0.97 | MDM4 (0.54) | MDM4TP53CASP3MDM2PPARA | |
| SCHEMBL3732493 | 0.97 | MDM4 (0.54) | MDM4TP53CASP3MDM2PPARA | |
| SCHEMBL119455 | 0.92 | MDM4 (0.59) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL1228254 | 0.92 | MDM4 (0.59) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL118169 | 0.92 | MDM4 (0.59) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL30291593 | 0.92 | MDM4 (0.59) | MDM4TP53CASP3MDM2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030050248-A1 | Novel amino acid and peptide inhibitors of Staphylococcus virulence | PANORAMA RESEARCH, INC. | 2003-03-13 | — | — | US | claimed |
| EP-1261362-A2 | NOVEL AMINO ACID AND PEPTIDE INHIBITORS OF STAPHYLOCOCCUS VIRULENCE | Intermune, Inc. (US) | 2002-12-04 | — | — | EP | claimed |
| WO-2001058471-A2 | NOVEL AMINO ACID AND PEPTIDE INHIBITORS OF STAPHYLOCOCCUS VIRULENCE | INTERMUNE, INC. (US) | 2001-08-16 | — | — | WO | claimed |
| EP-4748847-A1 | PEPTIDE COMPLEX HAVING VEGFR -2 AGONIST ACTIVITY | Peptidream Inc (JP) | 2026-05-27 | — | — | EP | disclosed |
| EP-4732286-A2 | COMPOSITIONS AND METHODS FOR ENCRYPTING, STORING, AND DECRYPTING INFORMATION IN OLIGOMERS | Board of Regents, The University of Texas System (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| WO-2025128624-A2 | HYBRID PEPTIDE COMPOUNDS HAVING A SUBSTITUTED TRYPTOPHAN RESIDUE OR A TERMINAL SUBSTITUENT | CARMOT THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250171494-A1 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-05-29 | — | — | US | disclosed |
| US-12281141-B2 | Method for synthesizing peptide containing N-substituted amino acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-04-22 | — | — | US | disclosed |
| WO-2025058677-A2 | COMPOSITIONS AND METHODS FOR ENCRYPTING, STORING, AND DECRYPTING INFORMATION IN OLIGOMERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-118812647-B | Novel insect short neuropeptide sNPF analogue and application thereof | 四川轻化工大学 | 2025-02-25 | — | — | CN | disclosed |
| WO-2001058471-A2 | NOVEL AMINO ACID AND PEPTIDE INHIBITORS OF STAPHYLOCOCCUS VIRULENCE | INTERMUNE, INC. (US) | 2001-08-16 | — | — | WO | disclosed |
| CN-1276785-A | N-aroylphenylalanine derivs. | HOFFMANNN LA ROCHE AG F (CH) | 2000-12-13 | — | — | CN | disclosed |
| EP-1005446-A1 | N-AROYLPHENYLALANINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-07 | — | — | EP | disclosed |
| WO-2000025768-A1 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| US-6018020-A | VIRICIDES WHICH ARE PROTEASE INHIBITORS AGAINST HEPATITIS C AND HEPATITIS G | HOFFMAN-LA ROCHE INC. (US) | 2000-01-25 | — | — | US | disclosed |
| EP-0941233-A2 | ANTIVIRAL PEPTIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-09-15 | — | — | EP | disclosed |
| WO-1999010313-A1 | N-AROYLPHENYLALANINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 1999-03-04 | — | — | WO | disclosed |
| US-5866684-A | Peptidyl inhibitors of viral proteases | HOFFMANN-LA ROCHE INC. (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1998022496-A2 | ANTIVIRAL PEPTIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171494-A1 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | NPPA, VIP, DNPEP | MDM4 4142/4885TP53 2781/4885CASP3 1091/4885 |
| US-12281141-B2 | Method for synthesizing peptide containing N-substituted amino acid | NPPA, VIP, DNPEP | MDM4 4142/4885TP53 2781/4885CASP3 1091/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | MDM4 441/4885TP53 34/4885CASP3 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.